DrugPatentWatch Database Preview
Drugs in Development Information for AKB-6548
» See Plans and Pricing
What is the drug development status for AKB-6548?
AKB-6548 is an investigational drug.
There have been 35 clinical trials for AKB-6548.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2017.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Anemia. The leading clinical trial sponsors are Akebia Therapeutics, Aerpio Therapeutics, and Mitsubishi Tanabe Pharma Corporation.
There are fourteen US patents protecting this investigational drug and one hundred and thirty-two international patents.
Summary for AKB-6548
| US Patents | 14 |
| International Patents | 132 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 50 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2017-08-01) |
| Vendors | 32 |
Recent Clinical Trials for AKB-6548
| Title | Sponsor | Phase |
|---|---|---|
| Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | Akebia Therapeutics Inc. | Phase 2 |
| Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | The University of Texas Health Science Center, Houston | Phase 2 |
| Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypotension or Open Angle Glaucoma | Aerpio Therapeutics | Phase 2 |
Clinical Trial Summary for AKB-6548
Top disease conditions for AKB-6548
Top clinical trial sponsors for AKB-6548
US Patents for AKB-6548
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AKB-6548 | Start Trial | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Akebia Therapeutics, Inc. (Cambridge, MA) | Start Trial |
| AKB-6548 | Start Trial | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | Akebia Therapeutics, Inc. (Cambridge, MA) | Start Trial |
| AKB-6548 | Start Trial | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Akebia Therapeutics, Inc. (Cambridge, MA) | Start Trial |
| AKB-6548 | Start Trial | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (Pajardo, PR) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AKB-6548
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AKB-6548 | Argentina | AR099354 | 2033-11-15 | Start Trial |
| AKB-6548 | Australia | AU2014348523 | 2033-11-15 | Start Trial |
| AKB-6548 | Australia | AU2019202144 | 2033-11-15 | Start Trial |
| AKB-6548 | Brazil | BR112016011065 | 2033-11-15 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
